Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line

11 Sept 2022

Abstract excerpt

Azacytidine (AzaC) and decitabine (AzadC) are cytosine analogs that covalently trap DNA methyltransferases, which place the important epigenetic mark 5-methyl-2'-deoxycytidine by methylating 2'-deoxycytidine (dC) at the C5 position. AzaC and AzadC are used in the clinic as antimetabolites to treat myelodysplastic syndrome and acute myeloid leukemia and are explored against other types of cancer. Although their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36089606
DOI: 10.1186/s13148-022-01329-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell linePMID 36089606Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesSemantic proximity Read ↗

Epigenetic anti-cancer treatment with a stabilized carbocyclic Decitabine analogueSemantic proximity Read ↗

Azacytidine causes complex DNA methylation responses in myeloid leukemiaSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesSemantic proximity Read ↗

Genomic impact of transient low-dose decitabine treatment on primary AML cellsSemantic proximity Read ↗

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatmentSemantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

DNA Methyltransferase Inhibitors and their Therapeutic PotentialSemantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.